A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Trial Profile

A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Tedizolid (Primary)
  • Indications Gram-positive infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Trius Therapeutics
  • Most Recent Events

    • 20 Apr 2010 Results were published as an abstract in the proceedings of the 20th European Congress of Clinical Microbiology and Infectious Diseases.
    • 10 Apr 2010 Tolerability results presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases.
    • 12 Sep 2009 Interim efficacy results have been presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top